Atrin Pharmaceuticals
3805 Old Easton Road
Doylestown
Pennsylvania
18902
United States
Tel: 215-589-6356
Fax: 215-489-4920
Website: http://atrinpharma.com/
Email: info@atrinpharma.com
About Atrin Pharmaceuticals
Atrin Pharmaceuticals is a dynamic biopharmaceutical firm focused on the discovery and development of proprietary medications. Using groundbreaking technology developed and licensed in association with the University of Pennsylvania, Atrin’s bioresearch has led to the development of a portfolio of drug candidates with multiple mechanisms of action. Atrin’s lead program is a novel series of first in class, water-soluble, orally bioavailable, highly potent small-molecule inhibitors of ATR for clinical application. Atrin’s pipeline of unique small molecules allows specific targeting of a broad spectrum of cancers (pancreatic, lung, ovarian, breast and colon) with much higher efficacy and lower toxicity than conventional chemotherapeutics. In addition to the ATR inhibitor series Atrin’s pipeline also contains two development candidates: ATRN-502, a p53 activator, and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. Atrin’s scientists have also invented the proprietary Atrize™ platform: an innovative phenotypic FACS-based screening that is broadly applicable across R&D, clinical applications and as an innovative tool for personalized medicine.YEAR FOUNDED:
2011
LEADERSHIP:
Founder and CEO: Oren Gilad
CFO: Bernard C. Rudnick
CMO:Rifat Pamukcu
5 articles about Atrin Pharmaceuticals
-
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
5/16/2022
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. (“Atrin”) and reported financial results for the three months ended March 31, 2022.
-
Atrin Pharmaceuticals Adds Critical Genomics Capabilities in Advance of Initiating First Clinical Trial Through Ongoing Collaboration with Predictive Technology Group
2/25/2020
Atrin Pharmaceuticals, a private biopharmaceutical company pioneering the discovery and development of proprietary molecules targeting DNA Damage and Repair (DDR) pathways to treat cancers that currently do not have effective therapies, today reported preliminary results from a collaborative genomics analysis that will be used to optimize patient selection for Atrin’s upcoming ATRN-119 clinical trial.
-
Predictive Technology Group and Atrin Pharmaceuticals Announce Molecular Diagnostic Oncology Development Collaboration
1/28/2020
Predictive Technology Group (OTC PINK: PRED) and Atrin Pharmaceuticals LLC are entering into a collaboration agreement to develop molecular diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with DNA Damage and Response (DDR) inhibitors, including Atrin’s and other small molecule ATR inhibitors
-
Atrin Pharmaceuticals Elects Jeffrey M. Dayno, MD To Board Of Directors
11/16/2016
-
Atrin Pharmaceuticals Appoints Gerhard J. Sperl, Ph.D. As Vice President, Chemistry, Manufacturing And Controls
10/25/2016